-
公开(公告)号：EP3873903A1
公开(公告)日：2021-09-08
申请号：EP19813990.9
申请日：2019-10-30
发明人： BALAN, Gayatri , BARTLETT, Mark J. , CHANDRASEKHAR, Jayaraman , CODELLI, Julian A. , CONWAY, John H. , COSMAN, Jennifer L. , KALLA, Rao V. , KASUN, Zachary A. , KIM, Musong , LEE, Seung H. , LO, Jennifer R. , LOYER-DREW, Jennifer A. , MITCHELL, Scott A. , PERRY, Thao D. , PHILLIPS, Gary B. , SALVO, Patrick J. , SWAMINATHAN, Sundaramoorthi , VAN VELDHUIZEN, Joshua J. , YEUNG, Suet C. , ZABLOCKI, Jeff
IPC分类号： C07D471/04 , C07D519/00 , A61K31/437 , A61P35/00
-
公开(公告)号：EP3154962B1
公开(公告)日：2019-08-07
申请号：EP15795017.1
申请日：2015-06-10
IPC分类号： C07D403/14 , C07D471/04 , C07D491/048 , A61K31/506 , A61P35/00
-
公开(公告)号：EP3154960A1
公开(公告)日：2017-04-19
申请号：EP15739038.6
申请日：2015-06-10
发明人： CAI, Shaopei , DU, Zhimin , KIM, Musong , LOYER-DREW, Jennifer, A. , NADUTHAMBI, Devan , PATEL, Leena , PHILLIPS, Barton, W. , PHILLIPS, Gary , STEVENS, Kirk, L. , TREIBERG, Jennifer, Anne , VAN VELDHUIZEN, Joshua , WATKINS, William, J. , YEUNG, Suet, Chung
IPC分类号： C07D403/12 , C07D401/14 , C07D403/14 , C07D473/34 , C07D487/04 , C07D513/04 , A61K31/517 , A61P35/00 , A61P37/00 , A61P25/28 , A61P3/08 , A61P9/10
CPC分类号： C07D403/12 , C07D401/14 , C07D403/14 , C07D405/14 , C07D413/14 , C07D471/04 , C07D473/34 , C07D487/04 , C07D513/04
摘要： The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein n, W, A′, B′, R1, R2, and R3 are described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.
摘要翻译： 本申请提供式（J）化合物或其药学上可接受的盐，异构体，互变异构体或其混合物，其中本文描述了n，W，A'，B'，R 1，R 2和R 3。 这些化合物是磷脂酰肌醇3-激酶（PI3K）活性的抑制剂，可用于治疗由一种或多种PI3K同种型介导的病症。 本申请还提供包含式（I）化合物或其药学上可接受的盐，异构体，互变异构体或其混合物的药物组合物，以及使用这些化合物和组合物治疗由一种或多种PI3K同种型介导的病症的方法。
-
公开(公告)号：EP4371987A1
公开(公告)日：2024-05-22
申请号：EP24150846.4
申请日：2019-10-30
发明人： BALAN, Gayatri , BARTLETT, Mark, J. , CHANDRASEKHAR, Jayaraman , CODELLI, Julian A. , CONWAY, John H. , COSMAN, Jennifer L. , KALLA, Rao V. , KASUN, Zachary A. , KIM, Musong , LEE, Seung H. , LO, Jennifer R. , LOYER-DREW, Jennifer A. , MITCHELL, Scott A. , PERRY, Thao D. , PHILLIPS, Gary B. , SALVO, Patrick J. , SWAMINATHAN, Sundaramoorthi , VAN VELDHUIZEN, Joshua J. , YEUNG, Suet C. , ZABLOCKI, Jeff
IPC分类号： C07D471/04 , C07D519/00 , A61P35/00 , A61K31/437
CPC分类号： C07D471/04 , C07D519/00 , A61P35/00
摘要： The present disclosure relates generally to certain 6-azabenzimidazole compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.
-
公开(公告)号：EP3154969B1
公开(公告)日：2019-10-09
申请号：EP15734488.8
申请日：2015-06-10
发明人： DU, Zhimin , EVARTS, Jerry , KAPLAN, Joshua , KIM, Musong , NADUTHAMBI, Devan , PATEL, Leena , PERREAULT, Stephane , PHILLIPS, Barton, W. , PHILLIPS, Gary , STEVENS, Kirk, L. , TREIBERG, Jennifer , VAN VELDHUIZEN, Joshua , WATKINS, William, J. , YEUNG, Suet, Chung
IPC分类号： C07D471/04 , C07D403/12 , C07D413/14 , C07D403/14 , C07D239/91 , C07D487/04 , C07D513/04 , A61P35/00 , A61P25/00 , A61K31/517
-
公开(公告)号：EP3478674A1
公开(公告)日：2019-05-08
申请号：EP17735754.8
申请日：2017-06-27
发明人： BALAN, Gayatri , CHOU, Chien-Hung , KIM, Musong , KIRSCHBERG, Thorsten A. , LINK, John O. , PHILLIPS, Gary , SAITO, Roland D. , SQUIRES, Neil H. , TAYLOR, James G. , WATKINS, William J. , WRIGHT, Nathan E.
IPC分类号： C07D403/12 , C07D401/14 , C07D405/14 , C07D417/14 , A61K31/517 , A61P35/00 , A61P29/00 , A61P3/10
摘要： The present disclosure relates generally to modulators of Cot (cancer Osaka thyroid) and methods of use and manufacture thereof.
-
公开(公告)号：EP3160960A1
公开(公告)日：2017-05-03
申请号：EP15739079.0
申请日：2015-06-23
发明人： EVARTS, Jerry , KAPLAN, Joshua , KIM, Musong , NADUTHAMBI, Devan , PATEL, Leena , PERRAULT, Stephane , PHILLIPS, Gary , PURVIS, Lafe, J., II , STEVENS, Kirk, L. , TREIBERG, Jennifer, A.
IPC分类号： C07D403/12 , C07D401/14 , C07D413/14 , C07D403/14 , C07D409/14 , C07D491/107 , A61K31/517 , A61P35/00 , A61P37/00 , A61P29/00
CPC分类号： C07D403/12 , C07D401/14 , C07D403/14 , C07D409/14 , C07D413/14 , C07D491/107
摘要： The present disclosure provides phosphatidylinositol 3-kinase (PI3K) inhibitors of formula (J), or pharmaceutically acceptable salts thereof, in which A, n, m, R
1 , R
2 , R
3 R
4 , R
5 , R
6 and R
7 are as defined herein. These compounds are useful for treatment of conditions mediated by one or more ΡI3Κ isoforms. The present disclosure further provides pharmaceutical compositions that include a compound of formula (J), or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by one or more PI3K isoforms.摘要翻译： 本公开提供了式（J）的磷脂酰肌醇3-激酶（PBK）抑制剂或其药学上可接受的盐，其中A，n，m，R 1，R 2，R 3，R 4，R 5，R 6和R 7如本文所定义。 这些化合物可用于治疗由一种或多种PI3K同种型介导的病症。 本公开进一步提供了包含式（J）化合物或其药学上可接受的盐的药物组合物，以及使用这些化合物和组合物治疗由一种或多种PI3K同种型介导的病症的方法。
-
公开(公告)号：EP3154969A1
公开(公告)日：2017-04-19
申请号：EP15734488.8
申请日：2015-06-10
发明人： DU, Zhimin , EVARTS, Jerry , KAPLAN, Joshua , KIM, Musong , NADUTHAMBI, Devan , PATEL, Leena , PERREAULT, Stephane , PHILLIPS, Barton, W. , PHILLIPS, Gary , STEVENS, Kirk, L. , TREIBERG, Jennifer , VAN VELDHUIZEN, Joshua , WATKINS, William, J. , YEUNG, Suet, Chung
IPC分类号： C07D471/04 , C07D403/12 , C07D413/14 , C07D403/14 , C07D239/91 , C07D487/04 , C07D513/04 , A61P35/00 , A61P25/00 , A61K31/517
CPC分类号： C07D513/04 , C07D239/91 , C07D401/14 , C07D403/12 , C07D403/14 , C07D413/14 , C07D473/34 , C07D487/04
摘要： The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, or a mixture thereof, wherein n, m, q, A′, W1, W2, W3, R1, R2, and R3 are described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.
摘要翻译： 本申请提供式（J）化合物或其药学上可接受的盐，异构体或其混合物，其中本文描述了n，m，q，A'，W1，W2，W3，R 1，R 2和R 3。 这些化合物是磷脂酰肌醇3-激酶（PI3K）活性的抑制剂，可用于治疗由一种或多种PI3K同种型介导的病症。 本申请还提供包含式（J）化合物或其药学上可接受的盐，异构体，互变异构体或其混合物的药物组合物，以及使用这些化合物和组合物治疗由一种或多种PI3K同种型介导的病症的方法。
-
9.发明公开
公开(公告)号：EP2125841A1
公开(公告)日：2009-12-02
申请号：EP07853345.2
申请日：2007-12-12
IPC分类号： C07F9/12 , C07F9/58 , C07F9/6503 , C07F9/6558 , A61K31/661 , A61K31/665 , A61K31/675 , A61P11/06
CPC分类号： C07F9/65038 , C07F9/12 , C07F9/581 , C07F9/65583 , C07F9/65586
摘要： A mutual prodrug of an AISTM and a β-agonist in formulation for delivery by aerosolization to inhibit pulmonary inflammation and bronchoconstriction is described. The mutual prodrug is preferably formulated in a small volume solution (10-500 μL) dissolved in a quarter normal saline having pH between about 5.0 and 7.0 for the treatment of respiratory tract inflammation and bronchoconstriction by an aerosol having mass median average diameter predominantly between about 1 to 5 μ, produced by nebulization or by dry powder inhaler.
-
公开(公告)号：EP4452415A1
公开(公告)日：2024-10-30
申请号：EP22854355.9
申请日：2022-12-20
发明人： BLOMGREN, Peter A. , DU, Zhimin , KIM, Musong , THOMAS-TRAN, Rhiannon , TUDESCO, Michael T. , VENKATARAMANI, Chandrasekar
IPC分类号： A61P35/00 , C07D401/12 , C07D401/14 , C07D413/14 , C07D417/14 , A61K31/4545
-
-
-
-
-
-
-
-
-
搜索结果
25 条记录 (耗时 0.03 秒)
